Bavarian Nordic

BAVA · Nasdaq Copenhagen · Healthcare

217.00DKK +0.1%last day

Price as of 2 October 2026

The price over the past year, with dividends: −5.1%

Performance

1 month

−1.1%

1 year

−5.1%

3 years, per year

+11.6%

5 years, per year

−8.7%

Largest fall, 3 years

−68.5%

Below the peak now

−46.0%

Volatility, 1 year

33.0%

Return with dividends reinvested.

Key figures

P/E

10.5

P/B

1.2

Dividend yield

0.0%

Return on equity

+11.7%

Net margin

+24.5%

Market value

2.5 bn USD

Quality, value and trend

Where Bavarian Nordic stands against every Nordic stock today. 100 is best.

Quality88

Profitability and a sound balance sheet over time. Better than 88% of Nordic stocks.

Value74

The price measured against earnings, assets and cash flow. Better than 74% of Nordic stocks.

Trend72

The price development over the past year. Better than 72% of Nordic stocks.

Combined95

Quality, value and trend together. Better than 95% of Nordic stocks.

About Bavarian Nordic

Bavarian Nordic is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 1,900 employees.

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis